December 10, 2024
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies...

Continue Reading
December 9, 2024
Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
MARLBOROUGH, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , announced that Nature Methods , one of the world’s leading scientific journals, has selected spatial proteomics as its prestigious “Method of the Year 2024” ,...

Continue Reading
November 14, 2024
Akoya Biosciences Reports Third Quarter 2024 Financial Results
MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. “Our third-quarter results came in below expectations, largely due to ongoing...

Continue Reading
November 5, 2024
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel
Pre-orders now available; early access available for select strategic partners for the PhenoCode IO60 panel – The Fastest Ultrahigh-plex Panel for Immuno-Oncology Research Launches the Mouse FFPE IO panel, optimized for pre-clinical immuno-oncology applications to drive translational research...

Continue Reading
October 28, 2024
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024....

Continue Reading
October 7, 2024
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust Akoya’s platforms will be used for deep spatial proteomic profiling of thousands of tissue samples from cancer patients to identify biomarkers...

Continue Reading
October 3, 2024
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company ® , today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who...

Continue Reading
August 5, 2024
Akoya Biosciences Reports Second Quarter 2024 Financial Results
MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc . (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the second quarter ending June 30, 2024. “Our second-quarter revenue showed a strong rebound with 26% sequential...

Continue Reading
July 15, 2024
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024....

Continue Reading
May 13, 2024
Akoya Biosciences Reports First Quarter 2024 Financial Results
MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the first quarter ending March 31, 2024. Business Highlights Revenue was $18.4 million in the first quarter of 2024,...

Continue Reading
Displaying 1 - 10 of 22

Search Investor Relations